Revolution Beauty Announces Settlement its Former CEO and Co-founder, Adam Minto

Revolution Beauty has made headlines with the announcement of a settlement reached with its former CEO and Co-founder, Adam Minto, concerning the events surrounding the delay in auditing the group’s FY22 results and the subsequent suspension of trading of its shares on AIM.

The terms of the agreement stipulate that Minto will pay the company approximately $3,7 million, disbursed over six annual installments. Additionally, both parties have agreed not to admit or accept liability.

Alistair McGeorge, the Non-Executive Chairman, expressed satisfaction with the resolution, stating that the company is delighted to have come to terms with Adam. This, coupled with the adjusted payment timetable finalized in December 2023 for the Medichem acquisition, enables the company to shift its attention to the future. He also shared his anticipation for an overview of the company’s strategy at the forthcoming Capital Markets Event scheduled for February 8, 2024.

Have you read?  
Hollywood: These Are The Most Expensive Flops In Movie History.
Top 10 Healthcare Leaders For 2023: Redefining Medical Innovations and Pharma Solutions
Here Are The Most Unmissable Travel Destinations In 2024.
10 legendary celebrities who, despite their passing, continue to earn millions in 2023.
Los Angeles Lakers Players with the Highest Earnings of All Time.

This report/news/ranking/statistics has been prepared only for general guidance on matters of interest and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, CEOWORLD magazine does not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.

Email Address*

Name